• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Biocon - Articles and news items

trastuzumab-biosimilar

EMA accepts to review Mylan and Biocon’s cancer biosimilar

Industry news / 25 August 2016 / Niamh Louise Marriott, Digital Content Producer

Mylan and Biocon, who co-developed this proposed biosimilar, anticipate that this may be the first MAA for a trastuzumab biosimilar accepted by the EMA…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +